Amgen, Cytokinetics, Royalty Pharma deal

Cytokinetics will receive $100 million in a deal with Royalty Pharma for royalties tied to heart failure candidate omecamtiv mecarbil (AMG 423). The biotech also said it will exercise an

Read the full 300 word article

User Sign In